Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”.

Go to Source